UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/650/0.1/14.01.26 | Market Closed - BOERSE MUENCHEN 20:41:47 28/06/2024 BST | ||
| 2.76 EUR | -3.83% |
|
| Current month | +9.09% | ||
| 1 month | +20.52% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 2.76 | -3.83% |
| 27/06/24 | 2.87 | 0.00% |
| 26/06/24 | 2.87 | +2.87% |
| 25/06/24 | 2.79 | -1.76% |
| 24/06/24 | 2.84 | +4.41% |
Real-time BOERSE MUENCHEN
Last update June 28, 2024 at 08:41 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD290Z |
| ISIN | DE000HD290Z3 |
| Date issued | 29/01/2024 |
| Strike | 650 $ |
| Maturity | 14/01/2026 (564 Days) |
| Parity | 10 : 1 |
| Emission price | 2.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.45 € |
|---|---|
| Lowest since issue | 1.14 € |
| Spread | 0.04 € |
| Spread % | 1.49% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
468.7
USD
Average target price
468.3
USD
Spread / Average Target
-0.10%
- Stock Market
- Warrants
- Warrant
